Accesswire
16 Oct 2025, 13:45 UTC · 50w ago
Verdict
Headline takes no side. We score LNAI +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
A study published in Nature Communications identified specific serum proteins (RGMA, ART3, ANTXR2) that reliably predict disease progression, such as loss of ambulation, in Duchenne Muscular Dystrophy.
More positive than 93% of claims this week
BioSymetrics, a subsidiary of Lunai Bioworks Inc. (NASDAQ:LNAI), provided key analytical support and led the integration of clinical and proteomic data for the study.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 87% of claims this week
The identified serum-based protein biomarkers enable disease progression prediction via a simple blood test, offering a minimally invasive alternative to motivation-dependent clinical scales.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Its subsidiary BioSymetrics provided key analytical support for a landmark study published in Nature Communications.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
14h ago
−86.9%
Price is moving against the score
$1.30 vs $9.92 close before publication (Oct 15) · not market-adjusted
LNAI chart →
